• PDF / 169,674 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 40 Downloads / 161 Views

DOWNLOAD

REPORT

---

1 S

Various toxicities: 11 case reports In a retrospective study involving 235 patients with advanced metastatic pancreatic ductal adenocarcinoma, who received gemcitabine and paclitaxel between 1 June 2013 and 1 July 2017, 11 patients [ages and sexes not stated] were described, who developed myalgia, neutropenia, thrombocytopenia, liver function test elevation, fever, leucocytosis, failure to thrive or flu like symptoms during treatment with gemcitabine and paclitaxel for the advanced metastatic pancreatic ductal adenocarcinoma. The patients, who had advanced metastatic pancreatic ductal adenocarcinoma, started receiving IV gemcitabine infusion (at 10 mg/m2/minute) and IV paclitaxel [nab-paclitaxel] infusion over 30 minutes as first-line (10 patients) or second-line (1 patient) treatments every 2 weeks [doses not stated]. However, the patients developed treatment related toxicities, which included myalgia (1 patient), grade II neutropenia (1 patient), grade III neutropenia (1 patient), grade II thrombocytopenia (1 patient), grade III thrombocytopenia (1 patient), grade I liver function test elevation (1 patient), fever (1 patient), leucocytosis (1 patient), failure to thrive (1 patient), flu like symptoms (1 patient) and grade III neutropenia and thrombocytopenia (1 patient) [time to reactions onsets not stated]. Therapy with gemcitabine and paclitaxel was discontinued in the patient, who developed myalgia [outcomes not stated] Rogers JE, et al. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. Cancer Medicine 9: 5406-5415, No. 15, Aug 2020. 803500855 Available from: URL: http://doi.org/10.1002/cam4.3229

0114-9954/20/1821-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 12 Sep 2020 No. 1821